Day One Biopharmaceuticals Inc
Day One Biopharmaceuticals — Q1 2025 Earnings Presentation
14 slides from Day One Biopharmaceuticals's earnings presentation, May 6, 2025
Slide 1: First Quarter 2025 Financial Results & Corporate Progress
MAY 2025 First Quarter 2025 Financial Results & Corporate Progress
Slide 2: Forward looking statements
Forward looking statements This presentation and the accompanying oral commentary contain forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements are inherently subject to risks and unc
Slide 3: Agenda & Day One Participants
Agenda & Day One Participants Opening Remarks Jeremy Bender (Chief Executive Officer) OJEMDATM (tovorafenib) Lauren Merendino (Chief Commercial Officer) Financial Performance Charles York (Chief Operating & Chief Financial Officer) Q&A Session All, joined by: Elly Barry (Chief Medical Officer)
Slide 4: Opening Remarks
Opening Remarks Jeremy Bender Chief Executive Officer
Slide 5: First quarter 2025 highlights
1 OJEMDA received U.S. FDA accelerated approval for relapsed or refractory BRAF-altered pediatric low-grade glioma on April 23, 2024. 2 Represents cash, cash equivalents and short-term investments as of March 31, 2025. First quarter 2025 highlights Financial Position $87.7M in net product revenue si
Slide 6: OJEMDA Launch Performance
OJEMDA Launch Performance Lauren Merendino Chief Commercial Officer
Slide 7: Commercial performance by the numbers
Commercial performance by the numbers $87.7M OJEMDA Net Product Revenue Since Launch1 $30.5M Q1 2025 OJEMDA Net Product Revenue 2,571 Cumulative Prescriptions Since Launch1,4 1 OJEMDA received U.S. FDA accelerated approval for relapsed or refractory BRAF-altered pediatric low-grade glioma on April 2
Slide 8: Continued OJEMDA revenue growth in Q1 2025
¹OJEMDA received U.S. FDA accelerated approval for relapsed or refractory BRAF-altered pediatric low-grade glioma on April 23, 2024. 2Q4 2024 revenue included approximately $1.4M of revenue associated with Ex-US sales which has been removed for the purposes of calculating quarter over quarter recurr
Slide 9: Prescriptions Since Launch
Prescriptions Since Launch 2 OJEMDA Prescriptions (TRx)1 +16% Strong commercial execution led to continued OJEMDA prescription growth in Q1 2025 Achieved 2,571cumulative scripts since launch Prescription Highlights Growth was driven by new patient starts and a high percentage of on-label patients co
Slide 10: OJEMDA has significant patient opportunity across priority centers
~230 pLGG Patients* per Center PRIORITY 1 17 centers OJEMDA has significant patient opportunity across priority centers PRIORITY 2 85 centers PRIORITY 3 110 Centers ~5,000 ~4,000 ~4,000 Estimated total patients managed by priority 1 centers Estimated patients managed by priority account is calculate
Slide 11: OJEMDA priorities to drive revenue growth in 2025
OJEMDA priorities to drive revenue growth in 2025 r/r, relapsed or refractory. Drive depth of prescribing with current prescribers Encourage non-user HCPs to try OJEMDA in their next r/r pLGG patient Establish OJEMDA as standard of care in 2nd line relapsed or refractory BRAF-altered pLGG Support pr
Slide 12: Financial Performance
Financial Performance Charles York Chief Operating Officer & Chief Financial Officer
Slide 13: First quarter 2025 financial results
All financial information is unaudited. 1 Includes stock-based compensation expense of $4.3 million for the three months ended 3/31/25, and $4.7 million for the three months ended 3/31/24. 2 Includes stock-based compensation expense of $8.6 million for the three months ended 3/31/25, and $8.0 millio
Slide 14: Thank You
Thank You
Day One Biopharmaceuticals — Q1 2025 Earnings Presentation on 6ix